Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report
| Autor: | Yuji Yamamoto, Manabu Morimoto, Itaru Endo, Kazuya Nakagawa, Kazuhisa Takeda, Chikara Kunisaki, Hitoshi Niino, Yu Kogure, Goro Matsuda, Tetsuya Shimizu, Hitoshi Sekido, Satoshi Kobayashi, Kentaro Araki, Koichi Mori, Yuji Tsurumaru |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Sorafenib
Male medicine.medical_specialty Carcinoma Hepatocellular Pyridines Hepatocellular carcinoma medicine.medical_treatment Antineoplastic Agents Vena Cava Inferior Case Report Budd-Chiari Syndrome Inferior vena cava Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Regorafenib Medicine Hepatectomy Humans Chemoembolization Therapeutic Vein Aged Chemotherapy IVC-HVTT business.industry Phenylurea Compounds Liver Neoplasms Gastroenterology General Medicine medicine.disease Thrombosis Combined Modality Therapy Surgery medicine.anatomical_structure chemistry medicine.vein 030220 oncology & carcinogenesis cardiovascular system 030211 gastroenterology & hepatology business Tomography X-Ray Computed medicine.drug |
| Zdroj: | Clinical Journal of Gastroenterology |
| ISSN: | 1865-7265 |
| Popis: | Regorafenib is an oral multikinase inhibitor affecting angiogenesis, oncogenesis, metastasis, and tumor immunity. As a systemic treatment, it has been shown to provide survival benefits in hepatocellular carcinoma (HCC) patients progressing on sorafenib treatment. We report herein a case of HCC with hepatic vein tumor thrombosis protruding into the inferior vena cava (IVC-HVTT) which was successfully treated by surgery following second-line chemotherapy with regorafenib. A 79-year-old man with chronic hepatitis was diagnosed with HCC. Computed tomography revealed a solitary tumor in segments 7 and 8 and an IVC-HVTT from the right hepatic vein. Since IVC-HVTT removal is a difficult procedure, the tumor was diagnosed as unresectable, and administration of sorafenib was started. Five weeks later, the lesion had increased in size by 15.3%; subsequently, regorafenib was given as second-line therapy for 12 months. After shrinkage of the IVC-HVTT, the patient was referred to our hospital for surgery. One month after the cessation of regorafenib, an extended resection of segment 8 and total removal of the IVC-HVTT was successfully performed without using total hepatic vascular exclusion. There were no serious postoperative complications. Additionally, there has been no recurrence for about 2 years since the initial therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink